AI Article Synopsis
- Researchers have developed antibodies with infinite affinity to enhance targeted delivery of metal complexes to disease sites.
- This innovation is part of a broader effort to advance chemical technology for biomedical imaging and therapy.
- The technique combines genetics and chemical synthesis to create proteins that securely bind synthetic molecules, allowing for effective capture of various metallic elements in physiological conditions.
Article Abstract
Antibodies with infinite affinity were developed with the aim of improving targeted delivery of metal complexes to sites of disease. This is part of a series of chemical technology developments for biomedical imaging and therapy. Using a combination of genetics and chemical synthesis, it addresses challenges in developing proteins that specifically bind synthetic molecules and do not release them. The result is a set of reagents that promise to capture any of a large variety of metallic elements under physiological conditions and hold them for long periods of time.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/ar020275e | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of autoantibody status on stratifying the risk of organ involvement and mortality in SSc: experience from a multicentre French cohort of 1605 patients.
RMD Open
November 2024
Department of Internal Medicine, Infectious Diseases, and Clinical Immunology, University Hospital Centre Reims, Reims, Grand Est, France.
Article Synopsis
- Systemic sclerosis (SSc) is a rare autoimmune disease classified into two groups based on skin involvement; this study investigates the role of autoantibody profiles in predicting organ damage and mortality compared to skin phenotype.
- Researchers analyzed data from 1,605 patients across seven French hospitals, focusing on autoantibodies and their correlation with various organ issues and death rates.
- Findings reveal that specific autoantibodies are strongly linked to serious complications like interstitial lung disease and renal crisis, while skin phenotype alone does not effectively predict patient outcomes.
Non-allergic Hypersensitivity Reactions to Immunoglobulin Preparations in Antibody Deficiencies: What Role for Anti-IgA IgG and Complement Activation?
Clin Rev Allergy Immunol
December 2024
Univ. Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.
Article Synopsis
- * Researchers measured the prevalence of IgG anti-IgA in PID patients compared to healthy controls and found a low percentage of PID patients with these antibodies and hypersensitivity.
- * The study suggests that complement activation might be a more significant factor in hypersensitivity reactions to immunoglobulin preparations, rather than just the presence of IgG anti-IgA.
Efficacy of vedolizumab and ustekinumab in pediatric-onset inflammatory bowel disease: A real-world multicenter study.
J Pediatr Gastroenterol Nutr
January 2025
Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, CHU Lille, Lille, France.
Objectives: Vedolizumab and ustekinumab are effective in inducing and maintaining corticosteroid-free clinical remission (CFR) in adult patients with inflammatory bowel disease (IBD). This study describes the efficacy and safety of vedolizumab and ustekinumab in pediatric IBD.
Methods: All patients ≤18 years of age with Crohn's disease (CD) or ulcerative colitis (UC) treated with vedolizumab or ustekinumab in three centers in Northern France were followed retrospectively.
An international survey to better understand the current incidence, severity, and management of VOD/SOS.
Bone Marrow Transplant
January 2025
Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
Article Synopsis
- * A significant number of respondents (67.0%) felt that early diagnosis was challenging, but many (75.8%) found the new 2023 EBMT diagnostic criteria useful and easy to apply.
- * Key risk factors for VOD/SOS included second allo-HCT, pre-existing liver disease, and prior use of antibody-drug conjugates, with varied preferences on when to start treatment.
Angioedema due to Acquired C1-Inhibitor Deficiency Associated With Monoclonal Gammopathies of Undetermined Significance Characteristics of a French National Cohort.
J Allergy Clin Immunol Pract
December 2024
Sorbonne Université, service de médecine interne, AP-HP, Hôpital Saint Antoine, Paris, France. Electronic address:
Article Synopsis
- MGUS-associated angioedema due to acquired C1 inhibitor deficiency (AAE-C1-INH) hasn't been specifically characterized before, prompting this study to explore its biological and clinical features over 30 years in France.
- In a study of 41 patients, most had anti-C1INH antibodies, and treatments included acute management and long-term prophylaxis, with a significant number developing malignant blood disorders like lymphoma or myeloma.
- The study found a link between the remission of angioedema and the underlying hematological malignancy, emphasizing the need for regular hematological evaluations in patients with MGUS-AE-C1-INH.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!